Skip to main content
BioCentury, the Bernstein Report on BioBusiness
As published for the week of Monday, January 30, 2012


  • Cover Story: Strategy: Roche re-sequences

    Roche: Illumina is key to tapping explosion in whole genome sequencing

    By Aaron Bouchie
    Senior Writer

    Roche already has the broadest set of molecular diagnostic technologies in the industry, and the pharma hopes acquiring Illumina Inc. will give it access to the biggest potential growth area in the MDx space: whole genome sequencing as routine clinical practice.

    That is why Roche offered $5.7 billion in a hostile bid for Illumina, although the final price will certainly be higher. Indeed, the biotech ended the week with a $6.3 billion market cap in shareholder anticipation of a white knight or an increased bid from Roche.

    Full Article

Money Raised in 2012

Last week, the biotech industry raised $154 million, bringing to $3.4 billion the total raised year-to-date. In 2011, a total of $49 billion was raised, including $36.7 billion in debt and other fundraising, $4.2 billion in follow-ons, $1.8 billion in PIPEs, $1 billion in IPOs, and $5.4 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial
BioCentury 20-Year Timeline

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Need custom ComputerVision Software?